Instil Bio Cuts Q1 R&D Spend 87%, Secures $74.7M Cash Runway Through 2027
TIL•Instil Bio ended Q1 2026 with $74.7 million in cash, cash equivalents and marketable securities, forecasting funding through 2027. Net loss per share narrowed to $0.62 GAAP and $0.32 non-GAAP, while R&D expenses fell to $0.7 million and G&A to $5.3 million year-over-year.
1. Q1 2026 Financial Results
Instil Bio reported a Q1 2026 net loss of $0.62 per share GAAP and $0.32 per share non-GAAP, compared to $4.32 and $1.32 per share in Q1 2025 respectively. Restructuring and impairment charges fell to $1.0 million from $16.1 million year-over-year.
2. Cash Position and Runway
Cash, cash equivalents, restricted cash and marketable securities totaled $74.7 million as of March 31, 2026, slightly down from $76.3 million at year-end. Management expects this balance to fund operations beyond 2027.
3. Expense Reduction and Loss Metrics
Research and development expenses declined to $0.7 million from $5.4 million year-over-year, while general and administrative costs dropped to $5.3 million from $9.1 million. The company attributes the reduction to restructuring efforts and cost discipline.
4. Strategic Update on Acquisitions
Instil Bio is actively evaluating potential acquisitions and in-licensing opportunities to strengthen its therapeutic pipeline. The company aims to leverage its cash position to pursue assets that complement its existing capabilities.
